| Element List | Current Period | Similar period for previous year | %Change | ||
|---|---|---|---|---|---|
| Sales/Revenue | 348,856 | 274,097 | 27.274 | ||
| Net profit (Loss) | -24,290 | -31,814 | -23.649 | ||
| Total Shareholders Equity (after Deducting Minority Equity) | 320,128 | 277,335 | 15.43 | ||
| Profit (Loss) per Share | -1.23 | -1.61 | |||
| All figures are in (Thousands) Saudi Arabia, Riyals | |||||
| Element List | Amount | Percentage of the capital (%) | |
|---|---|---|---|
| Profit (Losses) Resulting From The Change In Investment Propertie’s Fair Value | - | - | |
| All figures are in (Thousands) Saudi Arabia, Riyals | |||
| Element List | Explanation |
|---|---|
| The reason of the increase (decrease) in the sales/ revenues during the current period compared to the same period of the last year is | Arabian International Healthcare Holding Co. (“The Company” or “Tibbiyah”) reported revenue of SAR 348.9 million for H1-FY25, marking a 27.3% increase from SAR 274.1 million in H1-FY24. The increase was driven by FMS which contributed SAR 150.6 million, a 46.2% increase compared to the prior year, followed by the acquisition of Al-Hammad in July 2024, which contributed SAR 34.3 million. Premma managed to report steady revenue of SAR 130.6 million. The increase in revenue offset the declines in IHC. |
| The reason of the increase (decrease) in the net profit during the current period compared to the same period of the last year is | Arabian International Healthcare Holding Co. (“The Company” or “Tibbiyah”) registered a net loss attributable to shareholders of SAR 24.3 million in H1-FY25 (H1-FY24: loss of SAR 31.8 million) mainly due to: Revenues: Tibbiyah reported revenues of SAR 348.9 million in H1 2025 (H1 2024: SAR 274.1 million) represented a 27.3% increase year-on-year (YoY). The increase was driven by FMS which contributed SAR 150.6 million, a 46.2% increase compared to the prior year, followed by the acquisition of Al-Hammad in July 2024, which contributed SAR 34.3 million. Premma managed to report steady revenue of SAR 130.6 million. The increase in revenue offset the declines in IHC. Gross Profit: Gross profit of SAR 79.5 million in H1 2025 (H1 2024: SAR 62.0 million) represented an increase of 28.3% YoY, with margins rising to 22.8% (H1 2024: 22.6%). This improvement reflects the company’s successful project execution at FMS, the acquisition of Al-Hammad and a higher-margin portfolio mix at Premma. Net Loss: Net loss attributable to shareholders narrowed to SAR 24.3 million in H1 2025 compared to a net loss of SAR 31.8 million in H1 2024, primarily due to increased gross profit and lower impairment loss on trade receivables. |
| Statement of the type of external auditor's report | Unmodified conclusion |
| Reclassification of Comparison Items | None |
| Additional Information | Basic and diluted losses per share are calculated by dividing the losses for the period by the weighted average number of outstanding shares during the period. There were no potentially dilutive shares or options in the period, therefore no difference between the basic and the diluted losses per share. please refer to the attached File |
| Attached Documents | Attached Documents |
